Thivierge Caroline, Kurbegovic Almira, Couillard Martin, Guillaume Richard, Coté Olivier, Trudel Marie
Institut de Recherches Cliniques de Montreal, Molecular Genetics and Development, 110 ave. des Pins ouest, Montreal, Quebec, Canada H2W 1R7.
Mol Cell Biol. 2006 Feb;26(4):1538-48. doi: 10.1128/MCB.26.4.1538-1548.2006.
The pathogenetic mechanisms underlying autosomal dominant polycystic kidney disease (ADPKD) remain to be elucidated. While there is evidence that Pkd1 gene haploinsufficiency and loss of heterozygosity can cause cyst formation in mice, paradoxically high levels of Pkd1 expression have been detected in the kidneys of ADPKD patients. To determine whether Pkd1 gain of function can be a pathogenetic process, a Pkd1 bacterial artificial chromosome (Pkd1-BAC) was modified by homologous recombination to solely target a sustained Pkd1 expression preferentially to the adult kidney. Several transgenic lines were generated that specifically overexpressed the Pkd1 transgene in the kidneys 2- to 15-fold over Pkd1 endogenous levels. All transgenic mice reproducibly developed tubular and glomerular cysts and renal insufficiency and died of renal failure. This model demonstrates that overexpression of wild-type Pkd1 alone is sufficient to trigger cystogenesis resembling human ADPKD. Our results also uncovered a striking increased renal c-myc expression in mice from all transgenic lines, indicating that c-myc is a critical in vivo downstream effector of Pkd1 molecular pathways. This study not only produced an invaluable and first PKD model to evaluate molecular pathogenesis and therapies but also provides evidence that gain of function could be a pathogenetic mechanism in ADPKD.
常染色体显性多囊肾病(ADPKD)的发病机制仍有待阐明。虽然有证据表明Pkd1基因单倍体不足和杂合性缺失可导致小鼠囊肿形成,但矛盾的是,在ADPKD患者的肾脏中检测到了高水平的Pkd1表达。为了确定Pkd1功能获得是否可能是一个致病过程,通过同源重组对Pkd1细菌人工染色体(Pkd1-BAC)进行修饰,使其仅优先在成年肾脏中靶向持续的Pkd1表达。生成了几个转基因品系,其在肾脏中特异性过表达Pkd1转基因,比Pkd1内源性水平高2至15倍。所有转基因小鼠均反复出现肾小管和肾小球囊肿以及肾功能不全,并死于肾衰竭。该模型表明,单独过表达野生型Pkd1足以引发类似于人类ADPKD的囊肿形成。我们的结果还发现,所有转基因品系小鼠的肾脏c-myc表达显著增加,表明c-myc是Pkd1分子途径在体内的关键下游效应物。这项研究不仅产生了一个评估分子发病机制和治疗方法的宝贵的首个PKD模型,还提供了功能获得可能是ADPKD致病机制的证据。